Exhibit 99.1 Rapport Therapeutics Reports Second Quarter Financials and Provides Business Update • Completed initial public of ering, raising $174.4 million in gross proceeds, including full exercise of the underwriters' option to purchase additional shares and a concurrent private placement, to fund clinical development of precision neuroscience pipeline • Phase 2a trial of RAP-219 in focal epilepsy initiation on track, with topline data expected in mid-2025 • On track to begin two additional proof of conc ...